Novel Approaches in Post-TIL Combination Therapy Development
- Reintroducing checkpoint inhibitors after TIL, assessing safety and early signs of efficacy
- Setting benchmarks for post-TIL trials using emerging realworld data
- Identifying patient populations who may benefit from follow-up therapies after early TIL use